AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Core Points - AEON Biopharma, Inc. has successfully closed a public offering, raising approximately $20.0 million in gross proceeds [1][4] - The offering included 40,000,000 Common Units, each comprising one share of Common Stock and two types of warrants (Series A and Series B) with an exercise price of$0.625 [2][3] - Aegis Capital Corp. acted as the sole book-running manager for the offering and has a 45-day option to purchase additional shares and warrants to cover over-allotments [3][5] Financial Details - The public offering price per Common Unit was set at $0.50, and the total gross proceeds were approximately$20.0 million before expenses [1][4] - The Series A and Series B Warrants are exercisable following stockholder approval and have different expiration periods of 60 months and 30 months, respectively [2][3] Company Overview - AEON Biopharma is focused on developing a proprietary botulinum toxin complex, ABP-450, for medical conditions, with an initial emphasis on the neurosciences market [7][8] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use under the name Jeuveau and is approved as a biosimilar in Mexico and India [8] - The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in several regions, including the U.S., Canada, and the EU [8]